Page 3 - Biocon

Stocks to watch: ZEEL, Info Edge, NBCC, Biocon, United Breweries, SJVN

State-owned power giant NTPC has bagged 1.9 GW solar projects in CPSU Scheme-II tender

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance

Work on mRNA platform, antibodies for dengue, HIV in the plan

Sensex tanks 720 pts from day's high, ends 125 pts down; Nifty PSB drops 3%

On the weekly basis, the benchmark indices gained, thus taking their winning run to the fourth straight week

Stocks to watch: Biocon, Hero Moto, Poonawalla Fin, TVS Motor, bank stocks

Hero MotoCorp on Thursday said it will increase the price of its entire model range by up to Rs 3,000 from September 20

Biocon Biologics to offer 15% stake to Serum Institute Life Sciences

Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about $4.9 billion

SAT stays Biocon insider trading order

Sebi had directed Allegro Capital and its owner Kunal Kashyap to disgorge Rs 25 lakh for allegedly dealing in shares of Biocon while in possession of price sensitive information.

Top headlines: India sticks to growth forecast; Kerala struggles with Covid

Business Standard brings to you the top headlines on Friday

USFDA okays Biocon insulin Semglee as first interchangeable biosimilar drug

Semglee may now be substituted for Sanofi's Lantus by a pharmacist in the US

Coronavirus LIVE: 22k new cases in Kerala in a day; 6,258 in Maharashtra

India recorded 29,689 new coronavirus infections on Tuesday, which pushed its tally of Covid-19 cases to 31,440,951

Biocon partners Adagio for licence to make Covid-19 antibody cocktail

Treatment claims to address the resistant Delta variant as well

Biocon Biologics gets licence from Adagio for antibody Covid treatment

Initial data indicate that ADG20 could provide both rapid and durable protection against Covid-19 for up to one year

Biocon likely to seek full marketing authorisation for Covid-19 drug

Expects results from phase 4 study of itolizumab by end of this quarter

Biocon Q1 net profit declines 35% to Rs 108.4 cr; revenue at Rs 1807.8 cr

Biotechnology major Biocon has reported a 35.39 per cent decline in its consolidated net profit at Rs 108.4 crore for the quarter ended June 30, 2021 mainly on account of its share of loss in associate startup entity Bicara Therapeutics Inc. The company had posted a net profit of Rs 167.8 crore for the corresponding period of the previous fiscal, Biocon said in a late night filing on Thursday. Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was Rs 1,712.1 crore for the same period a year ago, it added. "Consolidated revenues, at Rs 1,808 crore, saw a muted growth on account of COVID-related operational challenges at Biocon's API facilities, both in Bengaluru and Hyderabad," Biocon Executive Chairperson Kiran Mazumdar-Shaw said. Q1FY22 P&L was also impacted by a share of loss in its Boston-based associate start-up entity, Bicara Therapeutics Inc, she added. "The outlook for the rest of the year is promising with several drug ...

Stocks to watch: Zomato, RIL, SBI Card, Voda Idea, Airtel, BPCL, Biocon

Forty-one companies, including RIL, JSW Steel, SBI Card, YES Bank and Federal Bank will report their quarterly numbers today

Top headlines: Parliament meets, firms face heat on independent valuation

Here are the top headlines on Monday morning

Biocon controversy: Sebi's insider trading laws may need an overhaul

Sebi regulations define "insider" as a company associate who is trading in the company's shares based on unpublished price sensitive information (UPSI) to make a quick buck

'Christie fiction': Biocon chief slams Sebi order on Allegro Capital

The case dates back to January 2018, when Biocon had announced an exclusive global collaboration with Sandoz on next-generation biosimilars

Sebi bars Allegro Capital for insider trading activities in Biocon shares

Sebi has barred Allegro Capital and one of its senior executives from the securities market for one year

Sebi bars Biocon's official from securities mkt for 3 months, levies fine

Regulator Sebi has restrained an official of Biocon Ltd from accessing the securities market for three months and also levied monetary penalty for contravening insider trading norms. Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018, The Securities and Exchange Board of India (Sebi) noted in an order passed late on Wednesday. Senior vice president of Biocon, Shreehas P Tambe, being an insider traded in the shares of the firm between December 19-27, 2017, in violation of market norms. Besides, Tambe also failed to make the timely requisite disclosures to Biocon pertaining to the trade for the sale of shares on December 19 and 20, 2017, where the sell value was more than Rs 10 lakh. As part of mandatory obligation under Prohibition of Insider Trading norms, Tambe was required to make disclosure within two trading days from the date of sale of shares

Covid has created an ecosystem of innovation in India: Kiran Mazumdar-Shaw

The ongoing Covid-19 public health crisis has resulted in the creation of an "ecosystem" of innovation in India, Biocon chief Kiran Mazumdar-Shaw has said